CR20130070A - Ensayos biomarcadores para detectar o medir inhibición de actividad quinasa tor - Google Patents
Ensayos biomarcadores para detectar o medir inhibición de actividad quinasa torInfo
- Publication number
- CR20130070A CR20130070A CR20130070A CR20130070A CR20130070A CR 20130070 A CR20130070 A CR 20130070A CR 20130070 A CR20130070 A CR 20130070A CR 20130070 A CR20130070 A CR 20130070A CR 20130070 A CR20130070 A CR 20130070A
- Authority
- CR
- Costa Rica
- Prior art keywords
- tor
- activity
- quinasa
- detect
- measure inhibition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
Abstract
Proporcionados en la presente se encuentran métodos para detectar y/o medir la inhibición de la actividad quinasa TOR en un sujeto y usos asociados con la misma.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US36945510P | 2010-07-30 | 2010-07-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
CR20130070A true CR20130070A (es) | 2013-05-20 |
Family
ID=45527332
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR20130070A CR20130070A (es) | 2010-07-30 | 2013-02-20 | Ensayos biomarcadores para detectar o medir inhibición de actividad quinasa tor |
Country Status (21)
Country | Link |
---|---|
US (1) | US20120028972A1 (es) |
EP (1) | EP2598885B1 (es) |
JP (1) | JP2013535684A (es) |
KR (1) | KR20130136970A (es) |
CN (1) | CN103119445B (es) |
AU (1) | AU2011282553B2 (es) |
BR (1) | BR112013002279A2 (es) |
CA (1) | CA2807147A1 (es) |
CO (1) | CO6680668A2 (es) |
CR (1) | CR20130070A (es) |
EC (1) | ECSP13012461A (es) |
ES (1) | ES2591135T3 (es) |
MX (1) | MX337907B (es) |
MY (1) | MY170983A (es) |
NI (1) | NI201300013A (es) |
NZ (1) | NZ606495A (es) |
RU (1) | RU2587040C2 (es) |
SG (1) | SG187659A1 (es) |
UA (1) | UA111724C2 (es) |
WO (1) | WO2012016113A1 (es) |
ZA (1) | ZA201300921B (es) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100048914A1 (en) | 2008-03-14 | 2010-02-25 | Angela Brodie | Novel C-17-Heteroaryl Steroidal Cyp17 Inhibitors/Antiandrogens, In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity |
EP3023433A1 (en) | 2009-02-05 | 2016-05-25 | Tokai Pharmaceuticals, Inc. | Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens |
CN107157990B (zh) | 2011-10-19 | 2020-01-07 | 西格诺药品有限公司 | 利用tor激酶抑制剂治疗癌症 |
BR112014020786A2 (pt) | 2012-02-24 | 2020-10-27 | Signal Pharmaceuticals, Llc | método para tratamento de câncer de pulmão, método para alcançar um critério de avaliação de resposta em tumores sólidos, método para aumento da sobrevivência |
CN108992446A (zh) * | 2012-03-15 | 2018-12-14 | 西格诺药品有限公司 | 用tor激酶抑制剂治疗癌症 |
AU2013203714B2 (en) * | 2012-10-18 | 2015-12-03 | Signal Pharmaceuticals, Llc | Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity |
SG11201505446WA (en) | 2013-01-16 | 2015-08-28 | Signal Pharm Llc | Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith |
US9884067B2 (en) | 2013-03-14 | 2018-02-06 | University Of Maryland, Baltimore | Androgen receptor down-regulating agents and uses thereof |
MX2015014599A (es) * | 2013-04-17 | 2016-03-03 | Signal Pharm Llc | Terapia de combinacion que comprende un inhibidor de tor cinasa y un analogo de citidina para tracar cancer. |
CA2908830C (en) * | 2013-04-17 | 2021-12-07 | Signal Pharmaceuticals, Llc | Treatment of cancer with dihydropyrazino-pyrazines |
WO2014172430A1 (en) * | 2013-04-17 | 2014-10-23 | Signal Pharmaceuticals, Llc | Combination therapy comprising a tor kinase inhibitor and n-(3-(5-fluoro-2-(4-(2-methoxyethoxy)phenylamino)pyrimidin-4-ylamino)phenyl)acrylamide for treating cancer |
SG10201801965RA (en) * | 2013-04-17 | 2018-04-27 | Signal Pharm Llc | Treatment of cancer with dihydropyrazino-pyrazines |
WO2014172429A1 (en) * | 2013-04-17 | 2014-10-23 | Signal Pharmaceuticals, Llc | Combination therapy comprising a tor kinase inhibitor and an imid compound for treating cancer |
TWI674897B (zh) * | 2013-04-17 | 2019-10-21 | 美商標誌製藥公司 | 藉二氫吡并吡化合物組合療法的癌症治療方法 |
BR112015026297B1 (pt) | 2013-04-17 | 2022-08-23 | Signal Pharmaceuticals, Llc | Uso de um inibidor da quinase tor e quinazolinona 5-substituída, composição farmacêutica que os compreende, e kit |
EA030726B1 (ru) | 2013-04-17 | 2018-09-28 | СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи | ФАРМАЦЕВТИЧЕСКИЕ СОСТАВЫ, СПОСОБЫ, ТВЕРДЫЕ ФОРМЫ И СПОСОБЫ ПРИМЕНЕНИЯ, ОТНОСЯЩИЕСЯ К 1-ЭТИЛ-7-(2-МЕТИЛ-6-(1H-1,2,4-ТРИАЗОЛ-3-ИЛ)ПИРИДИН-3-ИЛ)-3,4-ДИГИДРОПИРАЗИНО[2,3-b]ПИРАЗИН-2(1H)-ОНУ |
CN105407892B (zh) | 2013-05-29 | 2019-05-07 | 西格诺药品有限公司 | 一种化合物的药物组合物、其固体形式及它们的使用方法 |
WO2015023710A1 (en) | 2013-08-12 | 2015-02-19 | Tokai Pharmaceuticals, Inc. | Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies |
US9737535B2 (en) | 2014-04-16 | 2017-08-22 | Signal Pharmaceuticals, Llc | Methods for treating cancer using TOR kinase inhibitor combination therapy comprising administering substituted pyrazino[2,3-b]pyrazines |
US9512129B2 (en) | 2014-04-16 | 2016-12-06 | Signal Pharmaceuticals, Llc | Solid forms comprising 1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one and a coformer |
NZ714742A (en) | 2014-04-16 | 2017-04-28 | Signal Pharm Llc | Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use |
US9718824B2 (en) | 2014-04-16 | 2017-08-01 | Signal Pharmaceuticals, Llc | Solid forms comprising 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one, and a coformer, compositions and methods of use thereof |
NZ629796A (en) | 2014-07-14 | 2015-12-24 | Signal Pharm Llc | Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use |
KR20170024120A (ko) | 2014-07-14 | 2017-03-06 | 시그날 파마소티칼 엘엘씨 | 치환된 피롤로피리미딘 화합물을 사용한 암의 치료방법, 이의 조성물 |
CA3067585A1 (en) | 2017-06-22 | 2018-12-27 | Celgene Corporation | Treatment of hepatocellular carcinoma characterized by hepatitis b virus infection |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7135298B2 (en) * | 2003-03-26 | 2006-11-14 | The Burnham Institute For Medical Research | Screening assay for agents that alter target of Rapamycin activity |
WO2006122053A2 (en) * | 2005-05-09 | 2006-11-16 | Ariad Gene Therapeutics, Inc. | Biomarkers for evaluating likelihood of tumor sensitivity to an mtor inhibitor |
GB0509748D0 (en) * | 2005-05-13 | 2005-06-22 | Univ Glasgow | Materials and methods relating to cell based therapies |
WO2007061737A2 (en) * | 2005-11-17 | 2007-05-31 | Osi Pharmaceuticals, Inc. | FUSED BICYCLIC mTOR INHIBITORS |
AR057960A1 (es) * | 2005-12-02 | 2007-12-26 | Osi Pharm Inc | Inhibidores de proteina quinasa biciclicos |
KR20140104060A (ko) * | 2006-10-19 | 2014-08-27 | 시그날 파마소티칼 엘엘씨 | 헤테로아릴 화합물, 이들의 조성물 그리고 단백질 키나아제 억제제로서의 이들의 용도 |
US8110578B2 (en) * | 2008-10-27 | 2012-02-07 | Signal Pharmaceuticals, Llc | Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway |
-
2011
- 2011-07-28 US US13/192,792 patent/US20120028972A1/en not_active Abandoned
- 2011-07-29 UA UAA201302458A patent/UA111724C2/uk unknown
- 2011-07-29 BR BR112013002279A patent/BR112013002279A2/pt not_active IP Right Cessation
- 2011-07-29 AU AU2011282553A patent/AU2011282553B2/en not_active Ceased
- 2011-07-29 EP EP11813229.9A patent/EP2598885B1/en active Active
- 2011-07-29 CN CN201180046288.0A patent/CN103119445B/zh active Active
- 2011-07-29 SG SG2013007547A patent/SG187659A1/en unknown
- 2011-07-29 KR KR1020137005078A patent/KR20130136970A/ko not_active Application Discontinuation
- 2011-07-29 WO PCT/US2011/045842 patent/WO2012016113A1/en active Application Filing
- 2011-07-29 NZ NZ606495A patent/NZ606495A/en not_active IP Right Cessation
- 2011-07-29 ES ES11813229.9T patent/ES2591135T3/es active Active
- 2011-07-29 RU RU2013108840/15A patent/RU2587040C2/ru not_active IP Right Cessation
- 2011-07-29 MX MX2013001293A patent/MX337907B/es active IP Right Grant
- 2011-07-29 MY MYPI2013700174A patent/MY170983A/en unknown
- 2011-07-29 CA CA2807147A patent/CA2807147A1/en not_active Abandoned
- 2011-07-29 JP JP2013523221A patent/JP2013535684A/ja active Pending
-
2013
- 2013-01-30 NI NI201300013A patent/NI201300013A/es unknown
- 2013-02-04 ZA ZA2013/00921A patent/ZA201300921B/en unknown
- 2013-02-20 CR CR20130070A patent/CR20130070A/es unknown
- 2013-02-26 EC ECSP13012461 patent/ECSP13012461A/es unknown
- 2013-02-26 CO CO13038904A patent/CO6680668A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
MX2013001293A (es) | 2013-04-29 |
WO2012016113A1 (en) | 2012-02-02 |
CN103119445B (zh) | 2015-10-21 |
BR112013002279A2 (pt) | 2018-04-24 |
EP2598885A4 (en) | 2014-03-26 |
MY170983A (en) | 2019-09-23 |
UA111724C2 (uk) | 2016-06-10 |
RU2587040C2 (ru) | 2016-06-10 |
MX337907B (es) | 2016-03-28 |
CN103119445A (zh) | 2013-05-22 |
SG187659A1 (en) | 2013-03-28 |
KR20130136970A (ko) | 2013-12-13 |
EP2598885B1 (en) | 2016-07-20 |
CO6680668A2 (es) | 2013-05-31 |
NI201300013A (es) | 2013-04-19 |
CA2807147A1 (en) | 2012-02-02 |
JP2013535684A (ja) | 2013-09-12 |
AU2011282553B2 (en) | 2015-04-02 |
RU2013108840A (ru) | 2014-09-10 |
NZ606495A (en) | 2014-08-29 |
US20120028972A1 (en) | 2012-02-02 |
ECSP13012461A (es) | 2013-03-28 |
ES2591135T3 (es) | 2016-11-25 |
AU2011282553A1 (en) | 2013-03-14 |
ZA201300921B (en) | 2014-04-30 |
EP2598885A1 (en) | 2013-06-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CR20130070A (es) | Ensayos biomarcadores para detectar o medir inhibición de actividad quinasa tor | |
EP2901737A4 (en) | DETECTION OF MULTIPLE PATHS AND DETERMINATION OF POSITIONING MEASUREMENT ERRORS | |
TR201904386T4 (tr) | Nükleotidleri içeren nükleozomların saptanmasına yönelik yöntem. | |
BR112013021590A2 (pt) | detecção de capacitância em ensaio eletroquímico com resposta otimizada | |
HK1204648A1 (en) | Methods and devices for detection and measurement of analytes | |
BR112013014990A2 (pt) | dispositivo de medição, dispositivo de controle e aparelho de medição para medição de nível de enchimento | |
MX349561B (es) | Método para detectar nucleosomas que contienen variantes de histonas. | |
CO6801640A2 (es) | Ensayos interrogatorios basados en células y usos de los mismos | |
CL2013003802A1 (es) | Un dispositivo y metodo de medicion de gas para medir un gas en el estomago de un mamifero. | |
DK2036990T3 (da) | Diagnostisk test for følsomheden over for B-Raf-kinaseinhibitorer | |
IL236180B (en) | Biomarker test for prediction or early detection of preeclampsia and/or hellp syndrome | |
BR112012021590A2 (pt) | detecção de capacitância em ensaio eletroquímico | |
FR2995083B1 (fr) | Dispositif de detection et de mesure d'un defaut d'isolement | |
EP2835643A4 (en) | METHOD FOR DETECTING OR QUANTITATING ANALYSTS, KIT FOR DETECTING OR QUANTIFYING ANALYSTS AND TEST STRIPS FOR SIDEFLOW CHROMATOGRAPHY FOR DETECTING OR QUANTIFYING ANALYTES | |
HK1203625A1 (en) | Analyte meter test strip detection | |
GB201206977D0 (en) | An enzyme detection device | |
BR112015003931A2 (pt) | composição de teste para detecção de cãncer | |
TR201910112T4 (tr) | Plaka formunda bi̇r objeni̇n kalinliğinin ölçülmesi̇ i̇çi̇n ölçüm düzeneği̇ ve ölçüm yöntemi̇ | |
TN2015000325A1 (en) | Markers associated with wnt inhibitors | |
HK1231552A1 (zh) | 分析物測試儀測試條檢測 | |
WO2013036600A3 (en) | Measurement device with reader and disposable probe | |
BRPI1008243A2 (pt) | teste para detecção de tumor adrenal | |
CR20130208A (es) | Unidad de interfaz, sistema de medicion y un metodo en una unidad de interfaz | |
DK2384695T3 (da) | Målesystem til analytbestemmelse og fremgangsmåde | |
BR112013033950A2 (pt) | medidor de teste portátil com circuito de detecção de interferência |